Celera will license to Genentech a number of cell-surface targets that it discovered and validated using its proteomics platform. Genentech plans to validate these further and develop drugs against them. These drugs could be antibodies, antibody fragments, proteins, or small molecule drugs.
Celera Genomics will receive progess-dependent milestone payments and royalties on sales of any drugs developed. Celera Diagnostics retains the rights to develop certain diagnostics based on the targets.